Exacerbation Rate Reduction According to Baseline Blood Eosinophilic Count in Patients with Asthma Treated with ICS/LABA Maintenance and Reliever Therapy

被引：0
|
作者：
Brusselle, G. G. [1 ]
Papi, A. [2 ]
Nicolini, G. [3 ]
Santoro, L. [3 ]
Guastalla, D. [3 ]
机构：
[1] Ghent Univ Hosp, Ghent, Belgium
[2] Univ Ferrara, Ctr Asma, Ferrara, Italy
[3] Chiesi, Parma, Italy
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2019年 / 199卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1294
引用
收藏
页数：2
相关论文
共 33 条
  • [21] High Blood Eosinophil Concentrations And Serum Biomarkers Of Low Il-13 Pathway Activation At Baseline Predict Exacerbation Rate Reduction By Benralizumab For Patients With Moderate To Severe Asthma
    Newbold, P.
    Wu, Y.
    Shih, V.
    Liang, M.
    Vainshtein, I.
    Ranade, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [22] History Of Asthma Maintenance Medication Use And Asthma Exacerbation Risk Factors Before Initiation Of Inhaled Corticosteroid/long-acting β-agonist (ICS/LABA) Combination Therapy For Asthma: Comparison Of Budesonide/formoterol (BFC) And Fluticasone/salmeterol (FCS) In A US Commercially Insured Population
    Tunceli, O.
    Kern, D.
    Ramachandran, S.
    Pethick, N.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (02) : AB78 - AB78
  • [23] Efficacy of tezepelumab in patients with severe, uncontrolled asthma, according to baseline blood eosinophil count and allergic status: results from the phase 3 NAVIGATOR study
    Menzies-Gow, A.
    Corren, J.
    Cook, B.
    Kmita, K.
    Llanos-Ackert, J.
    Colice, G.
    Ambrose, C. S.
    ALLERGY, 2021, 76 : 21 - 22
  • [24] Late Breaking Abstract - SHAMAL: reduction of maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab: a randomised phase 4 study
    Jackson, David J.
    Heaney, Liam G.
    Humbert, Marc
    Kent, Brian D.
    Hiljemark, Lina
    Olinger, Lynda
    Cohen, David
    Menzies-Gow, Andrew
    Korn, Stephanie
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [25] Early reduction in circulating monocyte count predicts maintenance of remission in patients with rheumatoid arthritis treated with anti-TNF therapy
    Shipa, Muhammad Ruhul Amin
    Amarnani, Raj
    Yeoh, Su-Ann
    Mainuddin, M. D.
    Ehrenstein, Michael R.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (12) : 1628 - 1629
  • [26] Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study
    Jackson, David J.
    Heaney, Liam G.
    Humbert, Marc
    Kent, Brian D.
    Shavit, Anat
    Hiljemark, Lina
    Olinger, Lynda
    Cohen, David
    Menzies-Gow, Andrew
    Korn, Stephanie
    LANCET, 2024, 403 (10423): : 271 - 281
  • [27] Effect of Baseline Blood Eosinophil Level on Asthma Exacerbations Among Patients Treated with Benralizumab During the Oral Corticosteroid Reduction Phase of the PONENTE Trial
    Kwiatek, Justin
    Finch, Ryan
    Olinger, Lynda
    Katial, Rohit
    Heaney, Liam
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB12 - AB12
  • [28] Once-Daily Tiotropium Respimat® Add-on to at Least Ics Maintenance Therapy Demonstrates Improved Asthma Control in Patients with Symptomatic Asthma, Independent of Serum IgE or Blood Eosinophil Levels
    Vandewalker, Mark L.
    Virchow, Johann Christian
    Casale, Thomas B.
    Engel, Michael
    Moroni-Zentgraf, Petra
    Luehmann, Reinhold
    Dahl, Ronald
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (02) : AB210 - AB210
  • [29] Once-Daily Tiotropium Respimat® Add-on to at Least Ics Maintenance Therapy in Patients with Symptomatic Asthma: Methodology of Modeling Analyses By Serum IgE and Blood Eosinophil Levels
    Schmidt, Hendrik
    Moroni-Zentgraf, Petra
    Engel, Michael
    Dahl, Ronald
    Kerstjens, Huib A. M.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (02) : AB212 - AB212
  • [30] Effect of baseline long- acting muscarinic antagonist use on inhaled corticosteroid/ formoterol dose reduction in patients with severe eosinophilic asthma treated with benralizumab: SHAMAL post-hoc analysis
    Korn, S.
    Jandl, M.
    Humbert, M.
    Menzies-Gow, A.
    Shavit, A.
    Olinger, L.
    Jackson, D. J.
    ALLERGOLOGIE, 2024, 47 (09)
1234